Norway, March 31 -- Lifecare ASA (LIFE) has reached key development milestones and is transitioning from technology development towards product realisation and production, representing a strategic de-risking of the Company's path to commercialisation.As part of this development, the Board of Directors has resolved to centralise the Group's operations, with manufacturing activities to be established in Bergen, Norway, and chemistry-related activities to be consolidated within the Company's UK subsidiary in Bristol, United Kingdom.As a consequence of this strategic realignment, the Board has resolved to initiate the discontinuation of the business operations of its wholly owned subsidiary, Lifecare Germany GmbH, as part of an optimisation and...